Opthea (NASDAQ: OPT)
FY 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-30 | ||||||
REV |
H1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.107 | ||||||
REV | 91.218K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Opthea (NASDAQ: OPT) through any online brokerage.
Other companies in Opthea’s space includes: Macrogenics (NASDAQ:MGNX), Outlook Therapeutics (NASDAQ:OTLK), KalVista Pharma (NASDAQ:KALV), Vaxxinity (NASDAQ:VAXX) and 4D Molecular Therapeutics (NASDAQ:FDMT).
The latest price target for Opthea (NASDAQ: OPT) was reported by SVB Leerink on Tuesday, April 26, 2022. The analyst firm set a price target for 25.00 expecting OPT to rise to within 12 months (a possible 257.14% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Opthea (NASDAQ: OPT) is $7 last updated August 16, 2022, 6:06 PM UTC.
There are no upcoming dividends for Opthea.
Opthea’s FY earnings are confirmed for Tuesday, August 30, 2022.
There is no upcoming split for Opthea.
Opthea is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.